Leading pharmaceutical company Pfizer Inc has entered into a partnership with Ahmedabad-based Claris Lifesciences Ltd to commercialise sterile injectible drugs that are off-patent and have lost exclusivity in the United States, Canada, Australia, New Zealand and Europe.

These drugs cover a range of therapeutic areas, including anti-infectives, antibiotics and other critical care products.

CANCER drugs may soon come under the purview of India

President Obama engineered a political coup on Monday by bringing leaders of the health care industry to the White House to build momentum for his ambitious health care agenda.

Doctors, hospitals, drug makers and insurance companies will join President Obama on Monday in announcing their commitment to a sharp reduction in the growth of national health spending, White House officials said Sunday.

New Delhi: The government may have banned the distribution of Tamiflu and Relenza, two options available to battle the H1N1 influenza (or swine flu), but chemists say they are running out of stock despite selling Tamiflu at Rs 2,000 for 10 tablets.

Researchers can continue most experiments on mankind's closest relatives -- chimpanzees, gorillas and orangutans -- after European Union lawmakers watered down proposals to restrict testing.

The EU's executive Commission last year proposed a range of measures to improve the welfare of the 12 million vertebrate animals used in experiments each year, mostly mice and rats.

New Rules To Ensure 40-70% Cheaper Patented Medicines Reach Public System

THE government is laying ground rules for negotiating drug prices with multinational companies to ensure that costly patented drugs are provided at 40-70% lower prices through the public health system, compared with those prevailing in the private health care system.

Mumbai: The Indian clinical research industry has grown from Rs20crore to Rs1,500crore in the last three years.

May be the first new chemical entity developed and marketed by an Indian company.

Malvinder singhSix years after the Geneva-based, not-for-profit organisation, Medicines for Malaria Venture (MMV), made Ranbaxy its drug development partner, the latter today announced the start of final-stage clinical trials for a new anti-malaria drug.